Migalin5 mg

Migalin 5 mg is indicated for the management of neuropathic pain conditions caused by nerve damage or dysfunction.

It is commonly used for the treatment of:

• Diabetic Peripheral Neuropathic Pain (DPNP) – nerve pain associated with diabetes
• Postherpetic Neuralgia (PHN) – persistent nerve pain following shingles infection
• Peripheral Neuropathic Pain (PNP) – nerve pain due to peripheral nerve injury or disorders
• General Neuropathic Pain – chronic nerve-related pain conditions

Mirogabalin helps reduce pain signals from damaged nerves, improving quality of life in patients with chronic neuropathic pain conditions.

Adjunct anti-epileptic drugs, Primary anti-epileptic drug

Migalin 5 mg is a selective ligand of the α2δ subunit of voltage-gated calcium channels (VGCCs). By binding to these subunits, it reduces calcium influx into presynaptic neurons, leading to decreased release of excitatory neurotransmitters. This mechanism helps lower neuronal hyperexcitability in the central nervous system (CNS), resulting in relief from neuropathic pain.

After oral administration, Mirogabalin is rapidly absorbed, reaching peak plasma concentration within approximately 0.5 to 1.5 hours. It shows low plasma protein binding of around 25% and has a volume of distribution of 64–88 L, indicating wide tissue distribution.

The drug is primarily eliminated unchanged through the kidneys (approximately 61–72%) via glomerular filtration and active secretion. A small fraction (13–20%) undergoes hepatic metabolism via uridine diphosphate-glucuronosyltransferase (UGT) enzymes. The elimination half-life ranges from 2 to 4.9 hours, and nearly 99% of the drug is excreted via urine, with minimal fecal elimination.

Overall, Mirogabalin provides effective modulation of neuropathic pain by reducing abnormal neuronal signaling and stabilizing overactive nerve transmission.

Migalin 5 mg should be administered orally and the dose should be individualized based on patient response, tolerability, and renal function.

Adult Dose:
The recommended initial dose is 5 mg twice daily. The dose may be gradually increased by 5 mg increments at intervals of at least one week, up to a usual maintenance dose of 15 mg twice daily. Depending on clinical response and tolerability, the dose may be adjusted between 10 mg to 15 mg twice daily.

Pediatric Use:
Safety and efficacy in children and adolescents have not been established; therefore, use in this population is not recommended.

Hepatic Impairment:
No significant dose adjustment is required in patients with mild to moderate hepatic impairment after a single 15 mg dose. However, data are limited in severe hepatic impairment, and caution is advised.

Renal Impairment:
Dose adjustment is required based on renal function:

• Mild renal impairment: Start with 5 mg twice daily, titrate up to 10 mg twice daily
• Moderate renal impairment: Start with 2.5 mg twice daily, titrate up to 7.5 mg twice daily
• Severe renal impairment: Start with 2.5 mg once daily, titrate up to 7.5 mg once daily

Dose escalation should be done gradually at weekly intervals with careful monitoring of tolerability.

Migalin 5 mg has a low potential for clinically significant drug interactions, as it does not significantly inhibit or induce major CYP enzymes or common drug transporters. However, certain co-administered drugs may affect its plasma concentration or enhance its central nervous system (CNS) effects.

With medicines:

• Cimetidine, Probenecid: May increase plasma concentration of Mirogabalin by inhibiting renal transport pathways, potentially enhancing drug exposure.
• Lorazepam and other CNS depressants: May potentiate sedative and CNS depressive effects such as dizziness, drowsiness, and impaired coordination. Caution is advised when used together.
• OAT1, OAT3, OCT2, MATE1, MATE2-K, or UGT inhibitors: May increase Mirogabalin exposure; careful monitoring is recommended.

Mirogabalin itself does not significantly affect CYP enzymes or major drug transporters such as P-gp, BCRP, or OATP systems, making it relatively low-risk for pharmacokinetic interactions.

With food and other factors:
Food does not have a clinically significant effect on the absorption or overall exposure of Mirogabalin. It can be taken with or without food.

Migalin 5 mg is contraindicated in patients where its use may lead to safety risks or adverse hypersensitivity reactions.

Contraindications include:

• Hypersensitivity: Known allergy or hypersensitivity to Mirogabalin or any component of the formulation.
• Severe hepatic impairment: Use is contraindicated in patients with significant liver dysfunction where safety data are insufficient.
• Severe renal impairment (in certain labeling contexts): Depending on clinical guidelines, use may be restricted or contraindicated where appropriate dose adjustment is not feasible.

Mirogabalin should be used only under strict medical supervision, especially in patients with underlying organ dysfunction or known drug allergies.

Migalin 5 mg is generally well tolerated, but some patients may experience adverse effects, particularly during dose initiation or adjustment.

Common side effects include:

• Somnolence (drowsiness)
• Dizziness or lightheadedness
• Peripheral edema (swelling, especially in limbs)
• Weight gain

These effects are usually dose-related and may decrease with continued use.

Less common but serious adverse reactions:

• Severe dizziness, impaired consciousness, or fainting
• Marked drowsiness or loss of consciousness
• Signs of liver dysfunction: nausea, vomiting, loss of appetite, general weakness, or jaundice (yellowing of skin/eyes)

Patients experiencing severe or persistent symptoms should discontinue use and seek immediate medical attention.

Migalin 5 mg should be used during pregnancy and lactation only when the potential benefits clearly outweigh the possible risks to the mother and fetus or infant.

Pregnancy:
Limited data are available in human studies. Animal studies have shown placental transfer of Mirogabalin, suggesting potential fetal exposure. Therefore, it should be prescribed during pregnancy only if clearly necessary and under strict medical supervision.

Lactation (Breastfeeding):
Animal studies indicate that Mirogabalin may be excreted in breast milk. The potential risk to the breastfed infant cannot be ruled out. A decision should be made whether to discontinue breastfeeding or discontinue the drug, considering the importance of treatment for the mother.

Migalin 5 mg should be used with caution due to its central nervous system (CNS) effects and potential impact on daily activities and organ function.

Key precautions include:

• CNS effects: May cause dizziness, somnolence (drowsiness), or loss of consciousness. Patients should avoid driving, operating heavy machinery, or engaging in hazardous activities.
• Elderly patients: Increased risk of falls, fractures, and CNS side effects; careful monitoring is required.
• Weight gain: May occur during treatment and should be monitored regularly.
• Visual disturbances: Blurred vision or diplopia (double vision) may occur; medical evaluation is recommended if symptoms persist.
• Hypersensitivity reactions: Discontinue immediately if signs of allergic reaction occur and seek medical attention.
• Renal impairment: Dose adjustment is required in patients with kidney dysfunction to avoid increased drug exposure.
• Drug interactions: Caution is advised when used with other CNS depressants or medications affecting renal transport pathways; consult a physician before combination use.

General warning:
Patients should be fully informed about potential side effects and should use Mirogabalin only under proper medical supervision, especially in high-risk populations such as the elderly or those with renal impairment.

Store at below 30°C and dry place, away from light and moisture. Keep out of the reach of children.